TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24464530

Group type: EXPERIMENTAL
Intervention: Citalopram (2 × 20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22999835

Group type: EXPERIMENTAL
Intervention: Families for Safe Dates program
Number of subjects: 324
Study: 19490626

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS) used hourly (intervention group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nicotine nasal spray (NNS) used ad libitum (control group)
Number of subjects: 50
Study: 17305695

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) used for apexification in one appointment
Number of subjects: 50
Study: 15070877

Group type: EXPERIMENTAL
Intervention: Lidocaine vaginal gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine paracervical block
Number of subjects: 0
Study: 12160817

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% jelly
Number of subjects: 50

Group type: COMPARATOR
Intervention: BSS
Number of subjects: 50
Study: 9659024

Group type: EXPERIMENTAL
Intervention: Group D (13.5 ml at 12 ml.min‐1)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Large volumes of local anaesthetic
Number of subjects: 140

Group type: COMPARATOR
Intervention: Rate of injection and volume of local anaesthetic
Number of subjects: 140
Study: 7640328

Group type: EXPERIMENTAL
Intervention: Long-term cannabis use (duration measured in years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term cannabis use (frequency measured in use per time period)
Number of subjects: 0
Study: 31809601

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31524161

Group type: EXPERIMENTAL
Intervention: ReadClear (assistive reading app)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham condition (standard e-reader)
Number of subjects: 20
Study: 28234053

Group type: EXPERIMENTAL
Intervention: BI 671800 200 mg twice daily with fluticasone propionate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BI 671800 400 mg A.M. with fluticasone propionate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BI 671800 400 mg P.M. with fluticasone propionate
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo with fluticasone propionate
Number of subjects: 108
Study: 25980351

Group type: EXPERIMENTAL
Intervention: Combined antiretroviral therapy (cART)
Number of subjects: 0
Study: 24010986

Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride with 1:200,000 epinephrine (single buccal injection)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group received a single buccal injection and a single palatal injection before extraction
Number of subjects: 200
Study: 19725894

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 17278938

Group type: EXPERIMENTAL
Intervention: Exercise of moderate to high intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study: 15883638

Group type: EXPERIMENTAL
Intervention: Pamidronate (10 mg/m2/day IV for 3 days every 3 months)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no pamidronate)
Number of subjects: 18
Study: 12154425

Group type: EXPERIMENTAL
Intervention: Left-sided double-lumen tube (DLT) insertion using the best regression line
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Left-sided double-lumen tube (DLT) insertion verified using fiberoptic bronchoscopy
Number of subjects: 240
Study: 10190878

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillators
Number of subjects: 4595
Study: 7768075

Group type: EXPERIMENTAL
Intervention: Halofantrine 4.5 gm 7‐day loading dose regimen
Number of subjects: 20
Study: 2138683

Group type: EXPERIMENTAL
Intervention: B vitamins plus 75 mg diclofenac
Number of subjects: 123

Group type: COMPARATOR
Intervention: 75 mg diclofenac alone
Number of subjects: 123
Study: 7459427

Group type: EXPERIMENTAL
Intervention: U.K. sales tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Two tablet formulations
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aqueous solution
Number of subjects: 12
Study: 31454169

Group type: EXPERIMENTAL
Intervention: Health messages
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Well-being messages
Number of subjects: 207
Study: 31780640

Group type: EXPERIMENTAL
Intervention: RER (imaginal retraining with electronic reminders)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: RS (standard retraining without electronic reminders)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Both retraining groups (RER and RS)
Number of subjects: 384
Study: 28041599

Group type: EXPERIMENTAL
Intervention: 200mg of fermented soy containing 10mg of equol and 25mg of resveratrol (1 tablet/day)
Number of subjects: 60
Study: 25019600

Group type: EXPERIMENTAL
Intervention: Physical Activity in Rheumatoid Arthritis (PARA) coaching program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary physiotherapy
Number of subjects: 0
Study: 23963546

Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 80/5 mg
Number of subjects: 564

Group type: COMPARATOR
Intervention: Nifedipine GITS 30 mg
Number of subjects: 564
Study: 20409576

Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 3

Group type: COMPARATOR
Intervention: Neutral affect
Number of subjects: 3
Study: 20157862

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral social skills training (CBSST)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 62
Study: 17877953

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 15753494

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg(‐1), remifentanil 2 mug.kg(‐1), propofol 2 mg.kg(‐1) (Group P)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lidocaine 1.5 mg.kg(‐1), remifentanil 2 mug.kg(‐1), thiopental 5 mg.kg(‐1) (Group T)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Group P
Number of subjects: 76
Study: 11791811

Group type: EXPERIMENTAL
Intervention: Reflexology foot massage
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-reflexology foot massage (control)
Number of subjects: 34
Study: 9834264

Group type: EXPERIMENTAL
Intervention: L‐NMMA (NG‐monomethyl‐L‐arginine), a specific NO synthase blocker
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study: 8594676

Group type: EXPERIMENTAL
Intervention: Dot-blot enzyme-linked immunosorbent assay (dot-ELISA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Latex agglutination (LA)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Weil-Felix OX-19 test
Number of subjects: 121
Study: 2548548

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 974527

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aortography
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Adrenocortical scintigraphy
Number of subjects: 27
Study: 28622155

Group type: EXPERIMENTAL
Intervention: Documents with video message/testimonial (VM)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Documents only (Control)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Documents with VM
Number of subjects: 85
Study: 31751782

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU monthly)
Number of subjects: 5110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5110
Study: 31283730

Group type: COMPARATOR
Intervention: Alpha threshold of 0.05
Number of subjects: 200

Group type: COMPARATOR
Intervention: Power calculation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Main hypothesis p value < 0.005
Number of subjects: 200

Group type: COMPARATOR
Intervention: Main hypothesis p value between 0.005 and 0.05
Number of subjects: 200

Group type: COMPARATOR
Intervention: Main hypothesis p value > 0.05
Number of subjects: 200

Group type: COMPARATOR
Intervention: Smallest p value between 0.05 and 0.005
Number of subjects: 200

Group type: COMPARATOR
Intervention: Smallest p value < 0.005
Number of subjects: 200

Group type: COMPARATOR
Intervention: Smallest p value not provided or > 0.05
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cohort and database papers with main hypothesis p value < 0.005
Number of subjects: 200

Group type: COMPARATOR
Intervention: Randomized controlled trials with main hypothesis p value < 0.005
Number of subjects: 200

Group type: COMPARATOR
Intervention: Articles reporting power calculation with p value < 0.005
Number of subjects: 200

Group type: COMPARATOR
Intervention: Articles not reporting power calculation with p value < 0.005
Number of subjects: 200
Study: 29199184

Group type: EXPERIMENTAL
Intervention: scoliosis specific exercises (SSE) on a side‐alternating whole body vibration platform (sWBV) as a home‐training program for six months, five times per week.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular scoliosis specific exercises (SSE) as treatment as usual.
Number of subjects: 40
Study: 27410480

Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ad-libitum (AL) diet
Number of subjects: 218
Study: 25342183

Group type: EXPERIMENTAL
Intervention: Free-breathing (FB) CT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Expiratory breath-hold (BH) CT
Number of subjects: 52
Study: 21687997

Group type: EXPERIMENTAL
Intervention: Movement frequency at 1.33 Hz
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Movement frequency at 1.67 Hz
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Movement frequency at 1.84 Hz
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Movement frequency at 2.00 Hz
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Higher movement frequencies (1.67 Hz, 1.84 Hz, 2.00 Hz)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Comparison of MG and SOL
Number of subjects: 7
Study: 19237981

Group type: COMPARATOR
Intervention: Propofol induction in cannabis users (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol induction in nonusers (group NC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol induction in both groups
Number of subjects: 60
Study: 17472181

Group type: EXPERIMENTAL
Intervention: Self-etching primers as bonding agents underneath the composite resin restorations
Number of subjects: 80

Group type: COMPARATOR
Intervention: Other treatment protocols (not specified)
Number of subjects: 80
Study: 15853959

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once-daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 177
Study: 12064269

Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy body mass index
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Maternal height
Number of subjects: 188

Group type: COMPARATOR
Intervention: Maternal age
Number of subjects: 188

Group type: COMPARATOR
Intervention: Pregnancy weight gain
Number of subjects: 188
Study: 10468096

Group type: EXPERIMENTAL
Intervention: Presence of pericardial effusion
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Larger pericardial effusion
Number of subjects: 79
Study: 8562975

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 320 mg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Megestrol acetate treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cytokine production by peripheral blood lymphocytes
Number of subjects: 11
Study: 2235226

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg per day for 7 days, followed by hydrocortisone 8 mg/kg per day for 10 days)
Number of subjects: 23
Study: 760755

Group type: EXPERIMENTAL
Intervention: Intravenous heroin (2.5 mg and 5 mg) in non-dependent subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous heroin (1/6, 1/3, and 1/2 of prescribed doses) in dependent subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent oral methadone medication with heroin
Number of subjects: 0
Study: 31843975

Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor 50 U/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 30603015

Group type: EXPERIMENTAL
Intervention: TOF ratio ≥0.9 before extubation
Number of subjects: 168

Group type: COMPARATOR
Intervention: Clinical assessment of return of neuromuscular function
Number of subjects: 168
Study: 27278922

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 174

Group type: COMPARATOR
Intervention: NPH/Reg
Number of subjects: 174
Study: 24737258

Group type: EXPERIMENTAL
Intervention: Ulinastatin (200,000 IU) administered intravenously 12 hourly for 5 days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo administered intravenously 12 hourly for 5 days
Number of subjects: 122
Study: 22696608

Group type: EXPERIMENTAL
Intervention: Dual-mode weaning (n = 15)
Number of subjects: 32
Study: 20414709

Group type: EXPERIMENTAL
Intervention: 1 min infusion of 2 mg/kg of propofol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 min infusion of 2 mg/kg of propofol followed by a 29 min infusion of 12 mg kg(‐1) h(‐1) of propofol
Number of subjects: 21
Study: 17955229

Group type: EXPERIMENTAL
Intervention: 4 mg tizanidine (in nonsmokers)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 4 mg tizanidine (in male smokers)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Caffeine test (in male smokers)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 4 mg tizanidine (in females)
Number of subjects: 71
Study: 16477807

Group type: EXPERIMENTAL
Intervention: High stearic acid diet (shea butter)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High stearic acid diet (synthesized test fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High trans and oleic FA
Number of subjects: 0
Study: 12211509

Group type: EXPERIMENTAL
Intervention: Optimistically slanted information tape
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Tape featuring coping with more ups and downs
Number of subjects: 296

Group type: COMPARATOR
Intervention: No tape at all (control group)
Number of subjects: 296
Study: 10431125

Group type: EXPERIMENTAL
Intervention: Voucher incentive plus reminder-recall
Number of subjects: 565

Group type: COMPARATOR
Intervention: Voucher incentive alone
Number of subjects: 565
Study: 8701878

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1681044

Group type: EXPERIMENTAL
Intervention: 9% alpha-linolenic acid in intravenous lipids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast milk feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4.2% alpha-linolenic acid in intravenous lipids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Premature milk formula (Preemie Enfamil)
Number of subjects: 0
Study: 6636913

Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin (DDAVP) parenteral application (s.c., i.m., i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin (DDAVP)
Number of subjects: 10
Study: 31794244

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 168

Group type: COMPARATOR
Intervention: Comparison of Methylphenidate and Atomoxetine
Number of subjects: 168
Study: 31068225

Group type: EXPERIMENTAL
Intervention: Partner-assisted cognitive behavioural therapy for insomnia (PA-CBTI)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Traditional individual cognitive behavioural therapy for insomnia (i-CBTI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Partner-assisted sleep management therapy (PA-SMT)
Number of subjects: 120
Study: 27734232

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study: 27401980

Group type: EXPERIMENTAL
Intervention: e-cigarettes
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: dual users (substituted half of daily cigarette consumption with e-cigarettes)
Number of subjects: 105

Group type: COMPARATOR
Intervention: cessation (discontinued all nicotine and tobacco products)
Number of subjects: 105

Group type: COMPARATOR
Intervention: dual users
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: all groups
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: cessation and e-cigarette use groups
Number of subjects: 105
Study: 24637282

Group type: EXPERIMENTAL
Intervention: 4% hypertonic saline solution mouthwash
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regular tooth brushing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 22881048

Group type: EXPERIMENTAL
Intervention: Immediate comparison of procedures
Number of subjects: 198

Group type: COMPARATOR
Intervention: Delayed exposure to multiple procedures without comparison
Number of subjects: 198

Group type: COMPARATOR
Intervention: Delayed exposure to multiple procedures with comparison
Number of subjects: 198
Study: 19422079

Group type: EXPERIMENTAL
Intervention: Open arm with capnographic monitoring
Number of subjects: 263

Group type: COMPARATOR
Intervention: Blinded arm without capnographic monitoring
Number of subjects: 263
Study: 17954173

Group type: EXPERIMENTAL
Intervention: Automatic color image analysis for quantification of interstitial fibrosis (IF) on routine renal biopsy.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Serum creatinine levels at 3 years post-transplantation.
Number of subjects: 26
Study: 15516172

Group type: EXPERIMENTAL
Intervention: Nasal halitosis measurement using a portable sulfide monitor
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral halitosis measurement using a portable sulfide monitor
Number of subjects: 24
Study: 11825344

Group type: EXPERIMENTAL
Intervention: Kefir
Number of subjects: 13

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 13
Study: 9828635

Group type: EXPERIMENTAL
Intervention: 10 Gy radiation for occult CNV (n = 12)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group for occult CNV (n = 13)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 10 Gy radiation for classic CNV (n = 18)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group for classic CNV (n = 14)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 36 Gy radiation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 10 Gy radiation
Number of subjects: 57
Study: 7654113

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (quitters)
Number of subjects: 2684

Group type: COMPARATOR
Intervention: Continued smoking (smokers)
Number of subjects: 2684
Study: 3202338

Group type: EXPERIMENTAL
Intervention: Alcuronium (0.03 mg.kg‐1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Atracurium (0.04 mg.kg‐1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.01 mg.kg‐1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: D‐tubocurarine (0.05 mg.kg‐1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.01 mg.kg‐1)
Number of subjects: 53
Study: 31839310

Group type: EXPERIMENTAL
Intervention: ANFIS-BA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANFIS-GA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANFIS-ICA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ANFIS-PSO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standalone ANFIS model
Number of subjects: 0
Study: 30851066

Group type: EXPERIMENTAL
Intervention: Telmisartan 1.5 mg/kg PO q12h for 14 days, followed by 2 mg telmisartan/kg PO q24h
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo equivalent volume
Number of subjects: 221
Study: 29798560

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (ACB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single shot adductor canal block (ACB)
Number of subjects: 60
Study: 25399481

Group type: EXPERIMENTAL
Intervention: Azelaic acid 15% gel (AzA) for 9 months (AzA9M)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Azelaic acid 15% gel (AzA) for 3 months followed by observational phase (AzA3M)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel (AD9M) for 9 months
Number of subjects: 55
Study: 23398957

Group type: EXPERIMENTAL
Intervention: Health promotion intervention alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Health promotion and exercise intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual community care and delayed health promotion (control)
Number of subjects: 300
Study: 16963035

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/d for 12 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 36
Study: 14767410

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day divided into 4 doses of 5 g each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10397206

Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole (400 mg per day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8894809

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 58
Study: 1518122

Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) 10 mg/10 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP) 20 mg/20 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Panipenem/betamipron (PAPM/BP)
Number of subjects: 17
Study: 6412270

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) during treatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) during treatment
Number of subjects: 5
Study: 31494058

Group type: EXPERIMENTAL
Intervention: Treatment B (n=82) - received high-carotenoid FVs and weekly FV education
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Treatment A (n=61) - received high-carotenoid FVs
Number of subjects: 209

Group type: COMPARATOR
Intervention: Comparison group (n=66) - received neither FVs nor education
Number of subjects: 209